Hearing News Watch

Advanced Bionics (AB) has announced an equity investment and research collaboration with Spiral Therapeutics, as part of Spiral’s recently completed $27 million Series B financing, aimed at exploring new approaches to cochlear implant innovation and inner ear therapeutics. Spiral Therapeutics, a clinical-stage company developing therapies for inner ear disorders, said the financing was led by Gund Investment and included new

A new study led by researchers at Concordia University suggests that hearing ability plays a significant role in how older adults with mild cognitive impairment (MCI) manage everyday tasks that require both thinking and movement, such as walking while performing a mental activity. Drawing on data from the multi-center SYNERGIC clinical trial, the study also found that targeted exercise and

GAINESVILLE, FLORIDA — Neurotone AI has announced that audiologist and researcher Dr. Brian Taylor has joined the company as Vice President of Clinical Research and Professional Relations. In his new role, Dr. Taylor will support the company’s clinical research efforts, including the development of new studies, strengthening the evidence base for aural rehabilitation, and helping providers integrate brain-based hearing care

FARMINGTON HILLS, MICHIGAN — The International Hearing Society (IHS) is marking its 75th anniversary in 2026, recognizing its longstanding role in supporting hearing healthcare professionals who provide hearing evaluations and hearing aid services. The anniversary will be celebrated under the theme “Uniting Generations, Advancing Hearing Care,” with a focus on advocacy, relationships, communication, and education. According to the organization, these areas

HELSINKI, FINLAND — Deafmetal, a Finnish design-driven hearing health company focused on hearing aid jewelry and accessories, has announced the launch of a new Audiology Clinic Program alongside a €500,000 seed funding round to support international growth. The company’s approach centers on addressing one of the longstanding challenges in hearing care—adoption. According to the World Health Organization, only an estimated

SOMERSET, NEW JERSEY — The Oticon Hearing Foundation is continuing its partnership with the American Academy of Audiology Foundation (AAAF) through a $30,000 contribution aimed at supporting the professional development and humanitarian engagement of future audiologists. For the 2026–27 academic year, the Foundation will provide $20,000 toward student scholarships and up to $10,000 to support two student humanitarian mission trips

SCHAUMBURG, ILLINOIS — Natus Sensory, a global provider of sensory and diagnostic solutions, has announced a new strategic distribution partnership with Oaktree Products, a second-generation family-owned distributor of clinical supplies and diagnostic equipment serving the hearing healthcare industry. According to the companies, the partnership is intended to broaden access to Natus Sensory’s diagnostic hearing assessment and fitting solutions across the

MILAN, ITALY — Amplifon, parent company of Miracle-Ear and a global leader in hearing care services, today announced the appointment of Dr. Nicholas Reed to the newly created role of Vice President of Audiology Innovation and Research. In this role, Dr. Reed will oversee Amplifon’s research initiatives and support the company’s broader efforts in audiology and hearing health. He joins

AMSTERDAM, THE NETHERLANDS — Norgine B.V. announced that Swissmedic has granted marketing authorization for PEDMARQSI® (sodium thiosulfate solution for infusion) for the prevention of cisplatin-induced ototoxicity (hearing loss) in patients aged 1 month to <18 years with localized, non-metastatic solid tumors. The approval provides an authorized treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapy.

MONTPELLIER, FRANCE — Sensorion on Monday reported updated six-month efficacy data from Cohort 2 of its Phase 1/2 Audiogene trial evaluating SENS-501, while also providing a development update on its GJB2 gene therapy program, GJB2-GT (SENS-601). The company said the six-month follow-up data from Cohort 2 showed sustained early efficacy signals in two of three patients treated with the higher